Stock Events

Stock Events

Verona Pharma ADR 

$106.91
60
+$0.12+0.11% Monday 20:00

Statistics

Day High
106.91
Day Low
106.91
52W High
106.93
52W Low
31.6
Volume
1,871,051
Avg. Volume
2,193,944
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

29AprExpected
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Q3 2024
Q4 2024
Q1 2025
-0.8
-0.53
-0.27
0
Expected EPS
-0.03
Actual EPS
N/A

Financials

-409.78%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
42.28MRevenue
-173.25MNet Income

Analyst Ratings

$100.00Average Price Target
The highest estimate is 100.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VRNA. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline develops respiratory drugs, directly competing with Verona Pharma's treatments for respiratory diseases.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca has a strong portfolio in respiratory and inflammation treatments, overlapping with Verona Pharma's focus areas.
Champion Industries
CHMP
Mkt Cap960,449
Chiesi Farmaceutici, though not listed on a US exchange, competes in the global respiratory market, similar to Verona Pharma's target.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals focuses on cystic fibrosis, a specific area within the broader respiratory disease market that Verona targets.
Insmed
INSM
Mkt Cap40.44B
Insmed Incorporated offers therapies for rare lung diseases, competing in the niche market that Verona Pharma aims to serve.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap23.49B
Teva Pharmaceutical Industries has a broad portfolio that includes respiratory treatments, making it a competitor.
Novartis
NVS
Mkt Cap237.61B
Novartis AG has a diverse range of pharmaceuticals, including treatments for respiratory conditions, competing with Verona Pharma.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. develops drugs for various conditions, including respiratory diseases, making it a competitor.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. has a wide array of pharmaceutical products, including those for respiratory diseases, competing with Verona Pharma.
Biogen
BIIB
Mkt Cap22.63B
Biogen Inc. focuses on serious medical conditions, including respiratory diseases, though its main focus is on neurological conditions.

About

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Show more...
CEO
Dr. David Scott Zaccardelli Pharm.D.
Employees
209
Country
GB
ISIN
US9250501064

Listings

0 Comments

Share your thoughts

FAQ

What is Verona Pharma ADR stock price today?▼
The current price of VRNA is $106.91 USD — it has increased by +0.11% in the past 24 hours. Watch Verona Pharma ADR stock price performance more closely on the chart.
What is Verona Pharma ADR stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Verona Pharma ADR stocks are traded under the ticker VRNA.
Is Verona Pharma ADR stock price growing?▼
VRNA stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Verona Pharma ADR has showed a +77.33% increase.
What is Verona Pharma ADR revenue for the last year?▼
Verona Pharma ADR revenue for the last year amounts to 42.28M USD.
What is Verona Pharma ADR net income for the last year?▼
VRNA net income for the last year is -173.25M USD.
How many employees does Verona Pharma ADR have?▼
As of April 02, 2026, the company has 209 employees.
In which sector is Verona Pharma ADR located?▼
Verona Pharma ADR operates in the Health Care sector.
When did Verona Pharma ADR complete a stock split?▼
Verona Pharma ADR has not had any recent stock splits.
Where is Verona Pharma ADR headquartered?▼
Verona Pharma ADR is headquartered in London, GB.